MESO Q2 2024 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-14.4% YoY

Gross Profit

-$8M-472.4% margin

Operating Income

-$20M-1184.6% margin

Net Income

-$16M-960.4% margin

EPS (Diluted)

$-0.19

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$670M

Total Liabilities

$162M

Stockholders' Equity

$509M

Cash & Equivalents

$77M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$2M	-14.4%
Gross Profit	-$8M	-$14M	+41.1%
Operating Income	-$20M	-$21M	+5.0%
Net Income	-$16M	-$24M	+33.6%